{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:01Z","timestamp":1793317861616,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T00:00:00Z","timestamp":1399420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00198-014-2737-y","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T12:17:08Z","timestamp":1399378628000},"page":"2097-2107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength"],"prefix":"10.1007","volume":"25","author":[{"given":"B. P.","family":"Sinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Caird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Kozloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"2737_CR1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","volume":"7","author":"A Forlino","year":"2011","unstructured":"Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540\u2013557. doi: 10.1038\/nrendo.2011.81","journal-title":"Nat Rev Endocrinol"},{"key":"2737_CR2","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","volume":"310","author":"CR Paterson","year":"1984","unstructured":"Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694\u20131696. doi: 10.1056\/NEJM198406283102602","journal-title":"N Engl J Med"},{"key":"2737_CR3","doi-asserted-by":"crossref","unstructured":"Chevrel G, Schott A-M, Fontanges E et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300\u2013306. doi: 10.1359\/JBMR.051015","DOI":"10.1359\/JBMR.051015"},{"key":"2737_CR4","doi-asserted-by":"crossref","unstructured":"Adami S, Gatti D, Colapietro F et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126\u2013130. doi: 10.1359\/jbmr.2003.18.1.126","DOI":"10.1359\/jbmr.2003.18.1.126"},{"key":"2737_CR5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","volume":"87","author":"JR Shapiro","year":"2010","unstructured":"Shapiro JR, Thompson CB, Wu Y et al (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87:120\u2013129. doi: 10.1007\/s00223-010-9383-y","journal-title":"Calcif Tissue Int"},{"key":"2737_CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","volume":"23","author":"LA Bradbury","year":"2012","unstructured":"Bradbury LA, Barlow S, Geoghegan F et al (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285\u2013294. doi: 10.1007\/s00198-011-1658-2","journal-title":"Osteoporos Int"},{"key":"2737_CR7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","volume":"93","author":"D Gatti","year":"2013","unstructured":"Gatti D, Rossini M, Viapiana O et al (2013) Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 93:448\u2013452. doi: 10.1007\/s00223-013-9770-2","journal-title":"Calcif Tissue Int"},{"key":"2737_CR8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491\u2013498. doi: 10.1172\/JCI71101","journal-title":"J Clin Invest"},{"key":"2737_CR9","doi-asserted-by":"crossref","unstructured":"Poole KES, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842\u20131844. doi: 10.1096\/fj.05-4221fje","DOI":"10.1096\/fj.05-4221fje"},{"key":"2737_CR10","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883\u201319887. doi: 10.1074\/jbc.M413274200","journal-title":"J Biol Chem"},{"key":"2737_CR11","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin O, Piters E, Halleux C et al (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489\u201319500. doi: 10.1074\/jbc.M110.190330","journal-title":"J Biol Chem"},{"key":"2737_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. doi: 10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"2737_CR13","doi-asserted-by":"crossref","unstructured":"Li X, Ominsky MS, Warmington KS et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578\u2013588. doi: 10.1359\/jbmr.081206","DOI":"10.1359\/jbmr.081206"},{"key":"2737_CR14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J et al (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948\u2013959. doi: 10.1002\/jbmr.14","journal-title":"J Bone Miner Res"},{"key":"2737_CR15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. doi: 10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"2737_CR16","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","volume":"274","author":"A Forlino","year":"1999","unstructured":"Forlino A, Porter FD, Lee EJ et al (1999) Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an \u03b11(I) G349C substitution. J Biol Chem 274:37923\u201337931. doi: 10.1074\/jbc.274.53.37923","journal-title":"J Biol Chem"},{"key":"2737_CR17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1359\/JBMR.040111","volume":"19","author":"KM Kozloff","year":"2004","unstructured":"Kozloff KM, Carden A, Bergwitz C et al (2004) Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res 19:614\u2013622. doi: 10.1359\/JBMR.040111","journal-title":"J Bone Miner Res"},{"key":"2737_CR18","doi-asserted-by":"crossref","unstructured":"Uveges TE, Collin-Osdoby P, Cabral WA et al (2008) Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 23:1983\u20131994. doi: 10.1359\/jbmr.080804","DOI":"10.1359\/jbmr.080804"},{"key":"2737_CR19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","volume":"24","author":"TE Uveges","year":"2009","unstructured":"Uveges TE, Kozloff KM, Ty JM et al (2009) Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 24:849\u2013859. doi: 10.1359\/jbmr.081238","journal-title":"J Bone Miner Res"},{"key":"2737_CR20","doi-asserted-by":"crossref","unstructured":"Sinder BP, Eddy MM, Ominsky MS et al (2013) Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28:73\u201380. doi: 10.1002\/jbmr.1717","DOI":"10.1002\/jbmr.1717"},{"key":"2737_CR21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bone.2009.07.078","volume":"45","author":"JA Meganck","year":"2009","unstructured":"Meganck JA, Kozloff KM, Thornton MM et al (2009) Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD. Bone 45:1104\u20131116. doi: 10.1016\/j.bone.2009.07.078","journal-title":"Bone"},{"key":"2737_CR22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","volume":"9","author":"N Otsu","year":"1979","unstructured":"Otsu N (1979) A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 9:62\u201366","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"2737_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2818.1997.1340694.x","volume":"185","author":"T Hildebrand","year":"1997","unstructured":"Hildebrand T, R\u00fcegsegger P (1997) A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 185:67\u201375. doi: 10.1046\/j.1365-2818.1997.1340694.x","journal-title":"J Microsc"},{"key":"2737_CR24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bone.2006.08.018","volume":"40","author":"GM Reeves","year":"2007","unstructured":"Reeves GM, McCreadie BR, Chen S et al (2007) Quantitative trait loci modulate vertebral morphology and mechanical properties in a population of 18-month-old genetically heterogeneous mice. Bone 40:433\u2013443. doi: 10.1016\/j.bone.2006.08.018","journal-title":"Bone"},{"key":"2737_CR25","doi-asserted-by":"crossref","unstructured":"Parfitt AM, Drezner MK, Glorieux FH et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595\u2013610. doi: 10.1002\/jbmr.5650020617","DOI":"10.1002\/jbmr.5650020617"},{"key":"2737_CR26","unstructured":"Sinder B, Salemi J, Caird M, et al (2013) Sclerostin antibody increases cortical bone thickness in a rapidly growing Brtl\/+ model of OI by inducing bone formation on quiescent or resorbing surfaces. J Bone Miner Res 28 (Suppl 1)"},{"key":"2737_CR27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jbmr.548","volume":"27","author":"N Bivi","year":"2012","unstructured":"Bivi N, Condon KW, Allen MR et al (2012) Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 27:374\u2013389. doi: 10.1002\/jbmr.548","journal-title":"J Bone Miner Res"},{"key":"2737_CR28","doi-asserted-by":"crossref","unstructured":"Sinder B, White L, Caird M, et al (2012) Sclerostin antibody improves bone mass and mechanical properties in Brtl\/+ model of osteogenesis imperfecta when administered during growth. J Bone Miner Res 27 (Suppl 1)","DOI":"10.1002\/jbmr.1717"},{"key":"2737_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bone.2010.05.032","volume":"47","author":"X Tian","year":"2010","unstructured":"Tian X, Setterberg RB, Li X et al (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529\u2013533. doi: 10.1016\/j.bone.2010.05.032","journal-title":"Bone"},{"key":"2737_CR30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(98)00045-3","volume":"22","author":"T Kishi","year":"1998","unstructured":"Kishi T, Hagino H, Kishimoto H, Nagashima H (1998) Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: effects of long-term administration, withdrawal, and readministration. Bone 22:515\u2013522. doi: 10.1016\/S8756-3282(98)00045-3","journal-title":"Bone"},{"key":"2737_CR31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S8756-3282(98)00167-7","volume":"24","author":"M Li","year":"1999","unstructured":"Li M, Liang H, Shen Y, Wronski TJ (1999) Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 24:95\u2013100","journal-title":"Bone"},{"key":"2737_CR32","first-page":"E146","volume":"274","author":"JW Chow","year":"1998","unstructured":"Chow JW, Fox S, Jagger CJ, Chambers TJ (1998) Role for parathyroid hormone in mechanical responsiveness of rat bone. Am J Physiol 274:E146\u2013E154","journal-title":"Am J Physiol"},{"key":"2737_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bone.2008.06.008","volume":"43","author":"G Vanlenthe","year":"2008","unstructured":"Vanlenthe G, Voide R, Boyd S, Muller R (2008) Tissue modulus calculated from beam theory is biased by bone size and geometry: implications for the use of three-point bending tests to determine bone tissue modulus. Bone 43:717\u2013723. doi: 10.1016\/j.bone.2008.06.008","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2737-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2737-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T03:24:44Z","timestamp":1565407484000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,7]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2737"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2737-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718465259.793509203","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,7]]}}}